Editorial Board

Editorial Board

The Oncology Data Advisor® Editorial Board, led by Rahul Banerjee, MD, FACP, Assistant Professor of Medicine at Fred Hutchinson Cancer Center, collaborates to create compelling, clinically relevant content for our readers. Consisting of physicians, nurses, nurse practitioners, pathologists, pharmacists, and patient advocates, members provide comprehensive perspectives on all aspects of oncology care.

Rahul Banerjee, MD, FACP

Rahul Banerjee, MD, FACP, is an Assistant Professor in the Division of Medical Oncology at the University of Washington. He also holds a faculty appointment at the Fred Hutchinson Cancer Center in Seattle, Washington. Dr. Banerjee previously completed his Hematology/Oncology Fellowship and Advanced BMT/CAR-T Fellowship at the University of California, San Francisco. His clinical interests are in multiple myeloma, AL amyloidosis, and CAR-T therapy. His research interests are in toxicity management, digital health, and the patient experience.

Thomas Abrams, MD

Thomas Abrams, MD, is an Assistant Professor of Medicine at Harvard Medical School, an Institute Physician at Dana-Farber Cancer Institute, and Director of the Liver Cancer Task Force at Harvard Cancer Center. He specializes in the treatment of patients with gastrointestinal cancers, including pancreatic, gastric, colorectal, esophageal, gallbladder, anal, primary liver, and appendiceal cancers. Dr. Abrams’ primary research interest is the early detection of liver cancers through the discovery and application of novel biomarkers.

Ulka Vaishampayan, MD

Ulka Vaishampayan, MD, is a Professor of Internal Medicine and the Director of the Phase 1 Program at the University of Michigan Rogel Cancer Center. She is also the Chair of the SWOG Advanced Renal Committee, a member of the NCI Renal Task Force, and a board member of the Michigan Society of Hematology/Oncology. Dr. Vaishampayan specializes in the treatment of genitourinary malignancies, including prostate cancer, bladder cancer, and renal cell carcinoma, and her research focuses on translational drug development.

Richard D. Carvajal, MD

Richard D. Carvajal, MD, is Deputy Physician-in-Chief and Director of Medical Oncology at Northwell Health Cancer Institute in New York, where he is also the R.J. Zuckerberg Chair in Medical Oncology. Dr. Carvajal’s research is focused on the development of novel therapies for patients with melanoma and other cancers, including uncommon clinical and molecular subsets such as those arising from the eye (uveal melanomas), mucosal surfaces of the body (mucosal melanomas), and palms of the hands, soles of the feet, or under the fingernails (acral melanomas). He has been the principal or co-investigator of over 500 clinical trials and has authored or coauthored over 200 peer-reviewed manuscripts, books, and book chapters.

Lei Zhao, MD, PhD

Lei Zhao, MD, PhD, is an Assistant Professor of Pathology at Brigham and Women’s Hospital in Boston, Massachusetts. Her clinical interests focus on cancer genetics, metabolic syndrome, and gastrointestinal, liver, and surgical pathology. Dr. Zhao has published numerous peer-reviewed articles centered on improving outcomes of patients with gastrointestinal diseases.

Lauren Ghazal, PhD, FNP-BC

Lauren Ghazal, PhD, FNP-BC, is an Assistant Professor in the School of Nursing and an Associate Member in Cancer Prevention and Control at the University of Rochester Medical Center in New York. Her research focuses on nursing work-related challenges and financial toxicity experienced by adolescent and young adult cancer survivors, incorporating economic, clinical, and personal experiences to address survivorship disparities.

Jason Mouabbi, MD

Jason Mouabbi, MD, is in Assistant Professor in the Department of General Oncology and the Department of Breast Medical Oncology at The University of Texas MD Anderson Cancer Center, where he specializes in lobular breast cancers. His research focuses on the management of breast cancer subtypes and their impact on treatment. Dr. Mouabbi has been the recipient of multiple honors and awards, including the Guiding Researchers and Advocates to Scientific Partnerships (GRASP) Advocate Choice Award in 2022 and the Lester & Sue Smith Breast Cancer Award of Excellence in 2021.

Allison Rosen, MS

Allison Rosen, MS, is a colorectal cancer survivor and a patient advocate who uses her platform to educate, support, and represent the cancer community. She works as a patient advocate with numerous organizations, including Fight Colorectal Cancer, the National Coalition for Cancer Survivorship, the Colorectal Cancer Alliance, SWOG Cancer Research Network, and MD Anderson Cancer Center. Ms. Rosen is passionate about bridging the gap between the health care system and the communities that it serves.

Morana Vojnic, MD, MBA

Morana Vojnic, MD, MBA, is an Assistant Professor of Medicine in the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell Health and a Medical Oncologist at Lenox Hill Hospital, where she serves as Director of Oncologic Services in the Brain and Spine Metastases Program. She specializes in thoracic and neuro-oncology, with expertise in the treatment of lung cancer, mediastinal tumors, head and neck cancer, brain cancer, and metastatic lesions of the brain and spine. With a background in molecular genetics, Dr. Vojnic designs personalized treatment plans and protocols using targeted drugs, immunotherapy, and chemotherapy for the treatment of patients with these diseases.

Tristan Knight, MD, FRCPC

Tristan E. Knight, MD, FRCPC, is a Clinical Assistant Professor of Pediatrics at the University of Washington (Seattle, WA) and practices at Seattle Children’s Hospital. He completed his Pediatric Residency at the University of Hawaii, a Pediatric Hematology/Oncology Fellowship at the Children’s Hospital of Michigan, and a Bone Marrow Transplant (BMT)/Cellular Therapy Fellowship at the Hospital for Sick Children (SickKids). His clinical areas of interest are allogeneic/autologous BMT and cellular/immune effector cell therapy, particularly in the treatment of children with ALL, AML, and neuroblastoma. He has published extensively on novel therapeutic approaches in these conditions, including the use of CAR T-cell therapy in children.

Catherine Skefos, MA, MS, CGC

Catherine Skefos, MA, MS, CGC, is a Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas, MD Anderson Cancer Center, where she provides cancer risk assessment and counseling to patients in the Endocrine Center. As a genetic counselor working with both pediatric and adult patients, she helps patients and family members understand and adapt to information about inherited cancer risk and genetic testing. Prior to becoming a genetic counselor, she received an MA in Medical Anthropology from the University of South Florida, where her research focused on health care access and health disparity. Catherine has a special interest in teaching, particularly educating health care providers about the utility of genetic counseling and testing with the goal of improving patient access to genetic services.

Jethro Hu, MD

Jethro Hu, MD, is a Neuro-Oncologist at Cedars-Sinai Cancer and an Associate Professor in the Departments of Medicine, Neurology, and Neurosurgery at Cedars-Sinai Medical Center in Los Angeles, California. Dr. Hu specializes in the treatment of brain cancers, including glioma, glioblastoma, central nervous system (CNS) lymphoma, meningioma, and brain metastases. His research interests include the development of novel therapies and the impacts of diet on neuro-oncology outcomes.

Maria Badillo, MSN, RN, OCN®, CCRP

Maria Badillo, MSN, RN, OCN®, CCRP, is the Research Nurse Manager in the Mantle Cell Lymphoma/Myeloma Department at The University of Texas MD Anderson Cancer Center. As a clinical trial manager, she develops research strategies and programs, manages protocol design and implementation, and coordinates patient participation in phase 1, 2, and 3 clinical trials. Ms. Badillo's research focuses on the development of novel therapeutics for patients with hematologic malignancies and the management of adverse events to optimize treatment outcomes.

Richard F. Riedel, MD

Richard F. Riedel, MD, is an Associate Professor in the Division of Medical Oncology at Duke University Medical Center and the Associate Director of Clinical and Translational Research for the Duke Sarcoma Program. His clinical practice is dedicated to the care of patients with bone and soft tissue sarcoma, and his research interests lie in identifying novel therapies for these patients. Dr. Riedel is a member of the National Comprehensive Cancer Network (NCCN) Soft Tissue Sarcoma Guidelines Panel member and the NCCN Gastrointestinal Stromal Tumor (GIST) Guidelines Panel, and he is active in educational initiatives for sarcoma treatment.

Beth Sandy, MSN, CRNP

Beth Sandy, MSN, CRNP, is an Outpatient Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center in Philadelphia, Pennsylvania. She specializes in the treatment and supportive care of patients with lung cancer and other thoracic malignancies. Ms. Sandy has authored and coauthored numerous peer-reviewed publications, posters, and book chapters, and has been a speaker at several national and international conferences. She is a member of several professional societies and is active on committees and editorial boards for APSHO, IASLC, MASCC, ONS, and SITC.

Joseph Kalis, PharmD, BCOP

Joseph Kalis, PharmD, BCOP, is an Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health. In this position, he educates patients about their chemotherapy and immunotherapy treatments, reviews treatment plans and dose adjustments, and assists with supportive care. Dr. Kalis’ professional interests include multiple myeloma and hematologic malignancies. He enjoys teaching learners from all walks of life. Dr. Kalis has spoken extensively for continuing education programs, along with various peer-reviewed papers on oncology and pharmacy.

Megan-Claire Chase

Megan-Claire Chase is a patient advocate and the Breast Cancer Program Director for SHARE Cancer Support. As a survivor of stage IIA invasive lobular breast cancer, Ms. Chase became involved in patient advocacy work after completing her treatment. She is a prolific writer, blogger, and public speaker, having been featured in the New York Times, in People Magazine, and on PBS’s “Beyond Cancer” episode of “Stories from the Stage.” Her story and work are documented in her blog “Life on the Cancer Train.”

Stephen J. Freedland, MD

Stephen Freedland, MD, is Director of the Center for Integrated Research in Cancer and Lifestyle and Associate Director for Education and Training at the Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute in Los Angeles. He also is the Warschaw Robertson Law Families Chair in Prostate Cancer and a Professor in the Department of Urology at Cedars-Sinai. He also holds a Staff Physician appointment at the Durham VA Medical Center in Durham, North Carolina. Dr. Freedland has published over 700 articles and served on numerous AUA and ASCO guideline panels for prostate cancer. His research interests include the role of diet, lifestyle, and obesity in cancer, cancer health disparities, and cancer risk stratification.

Joseph Oropeza, PharmD, BCCCP

Joseph Oropeza, PharmD, BCCCP, is an Emergency Medicine and Critical Care Pharmacy Clinical Specialist at the University of Colorado Health. With a strong commitment to evidence-based care, he collaborates directly with providers and nurses to ensure the best possible outcomes for patients. Dr. Oropeza’s focus revolves around applying pharmaceutical expertise in emergency situations to deliver optimal care. He enjoys fostering two-way learning by not only contributing expertise but also engaging in continuous learning from colleagues and experiences. He takes pride in teaching and mentoring future learners and emphasizing critical thinking, problem-solving skills, and the importance of shared decision making in clinical scenarios.

Gurbakhash Kaur, MD

Gurbakhash Kaur, MD, is an Assistant Professor of Medicine in the Department of Internal Medicine at the University of Texas Southwestern Medical Center and Harold C. Simmons Comprehensive Cancer Center. She specializes in the treatment of patients with multiple myeloma, AL amyloidosis, and other plasma cell disorders, including the use of CAR T-cell therapy, immunotherapy, and stem cell transplantation. She actively participates in clinical trials investigating novel therapeutic options and quality-of-life improvements for patients with multiple myeloma.

Nagashree Seetharamu, MD

Nagashree Seetharamu, MD, is a Professor in the Department of Medicine, Division of Hematology and Oncology, at the Barbara and Donald Zucker School of Medicine at Hofstra/Northwell Health. In addition to being a nationally and internationally renowned thoracic and head and neck oncologist, with a busy clinical practice, she is a very active academician. She has conducted several research projects in the fields of lung cancer prevention, early detection, predicative and prognostic biomarkers, as well as novel therapeutics in thoracic and head and neck oncology. In addition, Dr. Seetharamu is passionate about mentoring the new generation of oncologists and plays an active role in the fellowship program at Northwell Health. She also serves as a mentor for trainees in other institutions through the ASCO mentorship program.

Hiam Abdel-Salam, MS, CGC

Hiam Abdel-Salam, MS, CGC, is a Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas, MD Anderson Cancer Center. She provides cancer risk assessment and counseling services to patients in MD Anderson’s Breast, Genitourinary, and Pediatric/Adolescent/Young Adult Centers. Her research interests are in the identification of incidental hereditary cancer predispositions in multigene panel testing and communication of hereditary cancer syndromes within families. She has a particular research focus on exploring attitudes and communication about cancer and hereditary cancer risk among racial and ethnic minority populations and improving access to cancer genetic counseling among underserved patients.
The Cancer Support Community is a global nonprofit that uplifts and strengthens people impacted by cancer. They are dedicated to fostering a community where people find connection, compassion, and knowledge. They provide professionally led support and navigation services, along with social connections and award-winning education—when, where, and how impacted individuals prefer throughout their cancer experience. These resources are available at 190 Cancer Support Community, Gilda’s Club, and healthcare partner locations as well as online and over the phone—all at no cost. They amplify the voices of those impacted by cancer through research and advocacy and create solutions that break down barriers to care and close the healthcare gap for communities whose members are disproportionately affected by cancer.